Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis

Completed · Phase 3

Conditions studied: Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).

In brief

To compare the efficacy of a 5-day course of clarithromycin extended-release tablets (2 x 500 mg QD) with that of a 7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID) in the treatment of acute bacterial exacerbation of chronic bronchitis.

Key facts

Study ID

NCT00645086

Run by

Abbott

People needed

465

Starts

2002-12-01

Last updated by the study team

2008-03-27

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ambulatory subject who does not require intravenous antibiotic therapy.
• Subject who has a medical history of chronic bronchitis.
• A history of regular medication use (>=3 consecutive months within the past 2 years) to treat pulmonary disease.
• Subject must have evidence of pulmonary function test abnormalities.
• The onset of signs and symptoms of the current exacerbation must occur within 14 days before Evaluation 1.

You may not qualify if…

• Medical history of hypersensitivity, allergic or adverse reactions to clarithromycin, erythromycin, or any of the macrolide antibiotics.
• A female who is pregnant or is lactating.
• Subject who has suspected or known (positive chest radiograph) pneumonia.
• Subject who has evidence of significant bronchiectasis (by CT) or atelectasis, active tuberculosis or other mycobacterial infection, bullous emphysema, pulmonary embolism, lung abscess, tumor (primary or metastatic) involving the lung, pleural effusion, or cystic fibrosis that could confound the assessment of signs and symptoms of ABECB.
• Subject who requires parenteral antibiotic therapy.
• Subject who requires hospitalization for treatment of current episode of ABECB.
• Subject who has any other infection or condition, which necessitates use of a concomitant systemic antibiotic.
• Subject who has any underlying condition/disease, which would be likely to interfere with the completion of the course or absorption of study drug therapy or follow-up.
• Subject who has a severe or complicated lower respiratory tract infection or a severely compromised respiratory status (i.e., oxygen dependent, requiring hospitalization).
• Known significant renal or hepatic impairment.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Columbiana, Alabama, United States
• Study site — Hoover, Alabama, United States
• Study site — Mobile, Alabama, United States
• Study site — Montgomery, Alabama, United States
• Study site — Ozark, Alabama, United States
• Study site — Glendale, Arizona, United States
• Study site — Phoenix, Arizona, United States
• Study site — Sun City West, Arizona, United States
• Study site — Tucson, Arizona, United States
• Study site — Tucson, Arizona, United States
• Study site — Camden, Arkansas, United States
• Study site — Clovis, California, United States
• Study site — Corona, California, United States
• Study site — Fountain View, California, United States
• Study site — Fresno, California, United States
• Study site — Huntington Beach, California, United States
• Study site — Lakewood, California, United States
• Study site — Pasadena, California, United States
• Study site — Rancho Cucamonga, California, United States
• Study site — Roseville, California, United States
• Study site — San Diego, California, United States
• Study site — San Diego, California, United States
• Study site — San Diego, California, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.